ADMA Biologics, Inc.ADMANASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank57
3Y CAGR+16.2%
5Y CAGR+11.4%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+16.2%/yr
vs -8.2%/yr prior
5Y CAGR
+11.4%/yr
Recent acceleration
Acceleration
+24.3pp
Accelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 8.50 | -8.8% |
| 2024 | 9.32 | +118.4% |
| 2023 | 4.27 | -21.3% |
| 2022 | 5.42 | +76.6% |
| 2021 | 3.07 | -38.2% |
| 2020 | 4.97 | -47.1% |
| 2019 | 9.38 | +23.1% |
| 2018 | 7.62 | +136.5% |
| 2017 | 3.22 | -52.7% |
| 2016 | 6.81 | - |